RKDA vs PGEN

For growth investors, Arcadia Biosciences, Inc.

(RKDA) is the stronger pick with -3. 7% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Analysts rate Precigen, Inc. (PGEN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Precigen, Inc.

(PGEN) delivered a total return of -36. 5%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: PGEN returned -84. 6% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Arcadia Biosciences, Inc.

(RKDA) is the lower-risk stock at 0. 98β versus Precigen, Inc. 's 1. 44β — meaning PGEN is approximately 47% more volatile than RKDA relative to the S&P 500.

By revenue growth (latest reported year), Arcadia Biosciences, Inc.

(RKDA) is pulling ahead at -3. 7% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -20. 5% for Precigen, Inc.. Over a 3-year CAGR, RKDA leads at -13. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Arcadia Biosciences, Inc.

(RKDA) is the more profitable company, earning -48. 1% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps -48. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RKDA leads at -205. 7% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — RKDA leads at 36. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Arcadia Biosciences, Inc.

(RKDA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Both have compounded well over 10 years (RKDA: -99. 9%, PGEN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RKDA (Basic Materials) and PGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.